VEDBAEK, Denmark, August 28 /PRNewswire-FirstCall/ -- Strong organic growth continued in Q2 2008 supported by new research product offerings. The development of Exiqon’s first molecular diagnostic product based on miRNA profiling remains on track for year end launch.
Lars Kongsbak, President and CEO says: “With financing in place to reach expected break even by 2011 and on track towards our goal of a cash flow positive life sciences business by the end of 2009, there is no doubt that Exiqon is in a sweet spot in the biotechnology market. We see a strong interest in miRNA and we are very excited about the launch of our first molecular diagnostic product based on miRNA by year end.”
For full report please click on the link:
http://exiqon.com/SEEEMS/10815.asp
CONTACT: Lars Kongsbak, CEO, phone +45-45-66-08-88 (cell:
+45-40-90-21-01); Hans Henrik Chrois Christensen, CFO, phone
+45-45-66-08-88 (cell: +45-40-90-21-31)
